US5688785A
(en)
*
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
CA2191455A1
(en)
*
|
1994-06-20 |
1995-12-28 |
Wayne Vaccaro |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US5624920A
(en)
*
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5633246A
(en)
*
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
DE69626128T2
(de)
*
|
1995-09-27 |
2003-11-27 |
Schering Corp |
Stereoselektiver, mikrobieller reduktionsprozess
|
EP0766962A3
(de)
*
|
1995-10-03 |
2000-05-10 |
Beiersdorf-Lilly GmbH |
Behandlung der Atherosclerose
|
US5843938A
(en)
*
|
1995-10-03 |
1998-12-01 |
Beiersdorf-Lilly Gmbh |
Treatment of atherosclerosis
|
AR004701A1
(es)
*
|
1995-10-31 |
1999-03-10 |
Schering Corp |
2-azetidinonas substituidas con azucares utiles como agentes hipocolesterolemicos, composicion farmaceutica, proceso para la preparacion dedicha composicion, uso de dichos compuestos para fabricar medicamentos y un equipo.
|
AU7472896A
(en)
*
|
1995-11-02 |
1997-05-22 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
|
DE69734321T2
(de)
|
1996-02-23 |
2006-08-10 |
Eli Lilly And Co., Indianapolis |
Non-peptidische vasopressin via antagonisten
|
US5739321A
(en)
*
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
US5886171A
(en)
*
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US5756470A
(en)
*
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
FR2762336B1
(fr)
*
|
1997-04-21 |
1999-06-11 |
Francois Trantoul |
Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
|
US6133001A
(en)
*
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
US5919672A
(en)
*
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
ATE297892T1
(de)
*
|
1998-12-07 |
2005-07-15 |
Schering Corp |
Verfahren zur herstellung von azetidinonen
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
PT1140187E
(pt)
*
|
1998-12-23 |
2004-01-30 |
Searle Llc |
Combinacoes de um inibidor de ibat e de um inibidor de mtp para indicacoes cardiovasculares
|
DK1140184T3
(da)
*
|
1998-12-23 |
2003-09-29 |
Searle Llc |
Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
|
KR20010102965A
(ko)
*
|
1998-12-23 |
2001-11-17 |
윌리암스 로저 에이 |
심장혈관의 징후에 대한 회장 담즙산 수송 저해제 및담즙산 격리제의 병용
|
WO2000038722A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle & Co. |
COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
|
EP1336413A1
(de)
*
|
1998-12-23 |
2003-08-20 |
G.D. Searle LLC. |
Kombinationen von Ileumgallensäuretransport-Inhibitoren und Fibrinsäurederivaten für kardiovaskuläre Indikationen
|
DK1140185T3
(da)
|
1998-12-23 |
2003-09-29 |
Searle Llc |
Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
|
CZ20012340A3
(cs)
*
|
1998-12-23 |
2001-11-14 |
G. D. Searle Llc |
Kombinace inhibitorů transportu kyčelní ľlučové kyseliny a proteinových inhibitorů cholesteryl-esterového přenosu pro kardiovaskulární indikace
|
NZ512534A
(en)
*
|
1998-12-23 |
2003-11-28 |
G |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
EP1169468B1
(de)
|
1999-04-05 |
2012-03-14 |
Schering Corporation |
Stereoselektive mikrobielle reduktion für die herstellung von 1-(4-fluorophenyl)-3(r)-¬3(s)-hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hydroxyphenyl)-2-azetidinon
|
US6297268B1
(en)
|
1999-11-30 |
2001-10-02 |
Schering Corporation |
Imidazoles as cholesterol lowering agents
|
US6586434B2
(en)
|
2000-03-10 |
2003-07-01 |
G.D. Searle, Llc |
Method for the preparation of tetrahydrobenzothiepines
|
US20020061888A1
(en)
*
|
2000-03-10 |
2002-05-23 |
Keller Bradley T. |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
US6584357B1
(en)
*
|
2000-10-17 |
2003-06-24 |
Sony Corporation |
Method and system for forming an acoustic signal from neural timing difference data
|
WO2002036124A2
(en)
*
|
2000-10-30 |
2002-05-10 |
Schering Corporation |
Treatment and method using loratadine and montelukast
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
EP1510521A1
(de)
*
|
2000-12-20 |
2005-03-02 |
Schering Corporation |
Zuckersubstituierte 2-Azetidinone Verwendbar als Hypocholesterdenische Arzneimittel
|
EP1593670B1
(de)
*
|
2000-12-20 |
2007-08-08 |
Schering Corporation |
Hydroxysubstituierte 2-Azetidinone verwendbar als Hypocholesterolemische Arzneimittel
|
SI1347987T1
(en)
|
2000-12-20 |
2005-02-28 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
IL156552A0
(en)
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
EP1345895B1
(de)
*
|
2000-12-21 |
2006-12-27 |
Sanofi-Aventis Deutschland GmbH |
Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
|
EP1911462A3
(de)
|
2001-01-26 |
2011-11-30 |
Schering Corporation |
Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
|
AU2008201609B8
(en)
*
|
2001-01-26 |
2009-01-08 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
SK9502003A3
(en)
*
|
2001-01-26 |
2003-12-02 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
AU2005246926B2
(en)
*
|
2001-01-26 |
2008-02-28 |
Merck Sharp & Dohme Corp. |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
AU2006203175B2
(en)
*
|
2001-01-26 |
2008-07-24 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
AU2007201970B2
(en)
*
|
2001-01-26 |
2008-04-17 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
RU2756946C2
(ru)
*
|
2001-01-26 |
2021-10-07 |
Мерк Шарп И Доум Корп. |
Применение замещенных азетидинонов для лечения ситостеролемии
|
EP1671650A1
(de)
*
|
2001-01-26 |
2006-06-21 |
Schering Corporation |
Kombinationen von einem Hemmer der Sterol-Absorption und Nicotinsäure zur Behandlung von kardiovaskulären Indikationen
|
AU2006202618B2
(en)
*
|
2001-01-26 |
2007-04-19 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
MXPA03006724A
(es)
*
|
2001-01-26 |
2003-10-24 |
Schering Corp |
Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares.
|
US20030053981A1
(en)
*
|
2001-01-26 |
2003-03-20 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
ATE348649T1
(de)
*
|
2001-01-26 |
2007-01-15 |
Schering Corp |
Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
|
TWI291957B
(en)
|
2001-02-23 |
2008-01-01 |
Kotobuki Pharmaceutical Co Ltd |
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
|
US6627757B2
(en)
*
|
2001-03-28 |
2003-09-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
WO2002096415A2
(en)
*
|
2001-05-25 |
2002-12-05 |
Schering Corporation |
Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
JP2005504091A
(ja)
*
|
2001-09-21 |
2005-02-10 |
シェーリング コーポレイション |
ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
|
EP1859796A3
(de)
*
|
2001-09-21 |
2008-07-02 |
Schering Corporation |
Behandlung von xanthom mit azetidinon-derivaten als hemmer der sterol absorption
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US6740663B2
(en)
*
|
2001-11-02 |
2004-05-25 |
G.D. Searle, Llc |
Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
|
US20030181520A1
(en)
*
|
2001-11-09 |
2003-09-25 |
Mitchell Glass |
Methods of reversing and preventing cardiovascular pathologies
|
WO2003053359A2
(en)
|
2001-12-19 |
2003-07-03 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
EP1465854A4
(de)
*
|
2001-12-19 |
2005-06-08 |
Atherogenics Inc |
Chalconderivate und deren verwendung zur behandlung von krankheiten
|
FR2833842B1
(fr)
*
|
2001-12-21 |
2004-02-13 |
Aventis Pharma Sa |
Compositions pharmaceutiques a base de derives d'azetidine
|
CA2471639A1
(en)
|
2002-01-17 |
2003-07-31 |
Pharmacia Corporation |
Novel alkyl/aryl hydroxy or keto thiepines.
|
US20050123580A1
(en)
*
|
2002-02-28 |
2005-06-09 |
Burris Thomas P. |
Method of treating atherosclerosis and hypercholesterolemia
|
US20040116510A1
(en)
*
|
2002-03-05 |
2004-06-17 |
Nichtberger Steven A. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
DE10227508A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
WO2004004665A2
(en)
|
2002-07-09 |
2004-01-15 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
US20040132058A1
(en)
|
2002-07-19 |
2004-07-08 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
US7135556B2
(en)
*
|
2002-07-19 |
2006-11-14 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
AR040588A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
CN1678296A
(zh)
|
2002-07-30 |
2005-10-05 |
卡里凯昂公司 |
依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法
|
WO2004056727A2
(en)
*
|
2002-12-19 |
2004-07-08 |
Atherogenics, Inc. |
Process of making chalcone derivatives
|
EP1601668B1
(de)
*
|
2003-03-07 |
2008-08-27 |
Schering Corporation |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
ES2318274T3
(es)
*
|
2003-03-07 |
2009-05-01 |
Schering Corporation |
Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
|
JP2006519869A
(ja)
*
|
2003-03-07 |
2006-08-31 |
シェーリング コーポレイション |
置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
|
EP1626954A2
(de)
*
|
2003-05-05 |
2006-02-22 |
Ranbaxy Laboratories, Ltd. |
Verfahren zur herstellung von trans-isomeren von diphenylazetidinonderivativen
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
US7923467B2
(en)
*
|
2003-05-30 |
2011-04-12 |
Ranbaxy Laboratories, Inc. |
Substituted pyrrole derivatives and their use as HMG-CO inhibitors
|
WO2005000217A2
(en)
*
|
2003-06-06 |
2005-01-06 |
Merck & Co., Inc. |
Combination therapy for the treatment of dyslipidemia
|
AU2004259747B2
(en)
*
|
2003-07-24 |
2009-02-19 |
Merck Frosst Canada Ltd |
Diphenyl substituted Cycloalkanes, compositions containing such compounds and methods of use
|
AU2003259547A1
(en)
*
|
2003-07-31 |
2005-02-14 |
Hetero Drugs Limited |
Ezetimibe polymorphs
|
EP1522541A1
(de)
*
|
2003-10-07 |
2005-04-13 |
Lipideon Biotechnology AG |
Neue hypocholesterolemische Verbindungen
|
WO2005042692A2
(en)
*
|
2003-10-31 |
2005-05-12 |
Forbes Medi-Tech Inc. |
A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
|
US20050096307A1
(en)
*
|
2003-11-05 |
2005-05-05 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
EP1918000A2
(de)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände
|
AU2004288822A1
(en)
*
|
2003-11-10 |
2005-05-26 |
Microbia, Inc. |
4-Biarylyl-1-phenylazetidin-2-ones
|
WO2005049592A1
(en)
*
|
2003-11-24 |
2005-06-02 |
Hetero Drugs Limited |
A novel process for ezetimibe intermediate
|
WO2005062824A2
(en)
|
2003-12-23 |
2005-07-14 |
Merck & Co., Inc. |
Anti-hypercholesterolemic compounds
|
CA2550215A1
(en)
*
|
2003-12-23 |
2005-07-07 |
Astrazeneca Ab |
Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
|
GB0329778D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
JP4590417B2
(ja)
*
|
2004-01-16 |
2010-12-01 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Npc1l1(npc3)およびこのリガンドの同定方法
|
PL1725234T5
(pl)
|
2004-03-05 |
2016-06-30 |
Univ Pennsylvania |
Sposoby leczenia zaburzeń lub chorób związanych z hiperlipidemią i hipercholesterolemią ze zminimalizowaniem efektów ubocznych
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050244367A1
(en)
*
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
PL1756049T3
(pl)
*
|
2004-05-21 |
2008-02-29 |
Sanofi Aventis Deutschland |
Sposób wytwarzania pochodnych 1,4-difenyloazetydynonu
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
US20060063828A1
(en)
*
|
2004-06-28 |
2006-03-23 |
Weingarten M D |
1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
US20070244107A1
(en)
*
|
2004-08-25 |
2007-10-18 |
Waters M Gerard |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
US20060046996A1
(en)
|
2004-08-31 |
2006-03-02 |
Kowa Co., Ltd. |
Method for treating hyperlipidemia
|
AR050631A1
(es)
*
|
2004-09-09 |
2006-11-08 |
Novartis Ag |
Combinacion de compuestos organicos
|
JP2008514718A
(ja)
*
|
2004-09-29 |
2008-05-08 |
シェーリング コーポレイション |
置換アゼチドノンおよびcb1アンタゴニストの組み合わせ
|
CN102558075A
(zh)
|
2004-12-03 |
2012-07-11 |
先灵公司 |
作为cb1拮抗剂的取代哌嗪
|
WO2006065709A2
(en)
*
|
2004-12-15 |
2006-06-22 |
Schering Corporation |
Functional assays for cholesterol absorption inhibitors
|
US20130082232A1
(en)
|
2011-09-30 |
2013-04-04 |
Unity Semiconductor Corporation |
Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
|
WO2006107936A1
(en)
*
|
2005-04-04 |
2006-10-12 |
Pontificia Universidad Catolica De Chile |
The use of ezetimibe in the prevention and treatment of cholesterol gallstones
|
TW200726746A
(en)
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
US20090292135A1
(en)
*
|
2005-05-09 |
2009-11-26 |
Ironwood Pharmaceuticals, Inc. |
Organometal benzenephosphonate coupling agents
|
MX2007014172A
(es)
*
|
2005-05-11 |
2008-04-02 |
Microbia Inc |
Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
BRPI0611415A2
(pt)
*
|
2005-05-25 |
2010-09-08 |
Microbia Inc |
ácidos fosfÈnicos de 4-(bifenilil)azetidin-2-ona e processo para a produção dos mesmos
|
WO2006138163A2
(en)
*
|
2005-06-15 |
2006-12-28 |
Merck & Co., Inc. |
Anti-hypercholesterolemic compounds
|
ES2337727T3
(es)
*
|
2005-06-20 |
2010-04-28 |
Schering Corporation |
Derivados de piperidina utiles como antagonistas de histamina h3.
|
US8013150B2
(en)
*
|
2005-06-22 |
2011-09-06 |
Msn Laboratories Ltd. |
Process for the preparation of ezetimibe
|
AR054482A1
(es)
*
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
SA06270191B1
(ar)
*
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
EP1741427A1
(de)
*
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Pharmazeutische Zusammensetzung enthaltend Simvastatin und Ezetimibe
|
US20070049748A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
EP1922304A2
(de)
|
2005-09-08 |
2008-05-21 |
Teva Pharmaceutical Industries Ltd |
Verfahren zur herstellung von (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinon, einem zwischenprodukt zur synthese von ezetimib
|
TW200806623A
(en)
*
|
2005-10-05 |
2008-02-01 |
Merck & Co Inc |
Anti-hypercholesterolemic compounds
|
KR20080059233A
(ko)
|
2005-10-21 |
2008-06-26 |
노파르티스 아게 |
레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
|
KR101329112B1
(ko)
*
|
2005-11-08 |
2013-11-14 |
랜박시 래보러터리스 리미티드 |
(3r,5r)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
|
HUP0501164A2
(en)
*
|
2005-12-20 |
2007-07-30 |
Richter Gedeon Nyrt |
New industrial process for the production of ezetimibe
|
JP2009521452A
(ja)
*
|
2005-12-21 |
2009-06-04 |
シェーリング コーポレイション |
コレステロール降下剤およびh3受容体アンタゴニスト/逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
|
WO2007119106A2
(en)
*
|
2005-12-22 |
2007-10-25 |
Medichem, S.A. |
Processes for preparing intermediate compounds useful for the preparation of ezetimibe
|
CA2637565A1
(en)
|
2006-01-18 |
2007-07-26 |
Schering Corporation |
Cannibinoid receptor modulators
|
JP5001252B2
(ja)
*
|
2006-02-16 |
2012-08-15 |
壽製薬株式会社 |
光学活性アルコールを製造する方法
|
WO2007100807A2
(en)
|
2006-02-24 |
2007-09-07 |
Schering Corporation |
Npc1l1 orthologues
|
EP1849459A1
(de)
*
|
2006-03-06 |
2007-10-31 |
Teva Pharmaceutical Industries Ltd. |
Ezetimibzusammensetzungen
|
US20070238716A1
(en)
*
|
2006-03-14 |
2007-10-11 |
Murthy Ayanampudi S R |
Statin stabilizing dosage formulations
|
US20080032964A1
(en)
*
|
2006-04-10 |
2008-02-07 |
Kansal Vinod K |
Process for the synthesis of azetidinone
|
AR060623A1
(es)
*
|
2006-04-27 |
2008-07-02 |
Astrazeneca Ab |
Compuestos derivados de 2-azetidinona y un metodo de preparacion
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
US20080153896A1
(en)
*
|
2006-07-14 |
2008-06-26 |
Gyan Chand Yadav |
Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof
|
JP2009503119A
(ja)
*
|
2006-08-29 |
2009-01-29 |
テバ ファーマシューティカル インダストリーズ リミティド |
(3r,4s)−4−(4−ヒドロキシ保護−フェニル)−1−(4−フルオロフェニル)−3−[3−(4−フルオロフェニル)−3−オキソプロピル]アゼチジン−2−オンを精製する方法
|
US20080103122A1
(en)
*
|
2006-09-05 |
2008-05-01 |
Schering Corporation |
Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
|
US20080076750A1
(en)
*
|
2006-09-15 |
2008-03-27 |
Aslanian Robert G |
Azetidinone Derivatives and Methods of Use Thereof
|
CN101541795A
(zh)
*
|
2006-09-15 |
2009-09-23 |
先灵公司 |
用于治疗疼痛、糖尿病和脂类代谢紊乱的螺-稠合氮杂环丁烷衍生物
|
CA2663502A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Azetidinone derivatives and methods of use thereof
|
WO2008033431A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
|
KR20090071589A
(ko)
|
2006-09-15 |
2009-07-01 |
쉐링 코포레이션 |
통증 및 지질 대사 장애의 치료에 유용한 아제티딘 및 아제티돈 유도체
|
US20080085315A1
(en)
*
|
2006-10-10 |
2008-04-10 |
John Alfred Doney |
Amorphous ezetimibe and the production thereof
|
CN100564357C
(zh)
*
|
2006-10-20 |
2009-12-02 |
浙江天宇药业有限公司 |
一种氮杂环丁酮衍生物及其合成方法
|
AU2007342603A1
(en)
*
|
2006-12-20 |
2008-07-17 |
Merck Sharp & Dohme Corp. |
Anti-hypercholesterolemic compounds
|
EP1939174A1
(de)
*
|
2006-12-21 |
2008-07-02 |
LEK Pharmaceuticals D.D. |
Einschlusskomplex von Ezetimib und einem Cyclodextrin und Verfahren zu seiner Herstellung
|
US20080161279A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Wisler Gerald L |
Methods of Treating Obesity
|
CN102285906B
(zh)
*
|
2007-01-24 |
2014-11-19 |
克尔克公司 |
依泽替米贝的制备方法和其的衍生物
|
WO2008096372A2
(en)
*
|
2007-02-06 |
2008-08-14 |
Ind-Swift Laboratories Limited |
Process for preparing highly pure ezetimibe using novel intermediates
|
WO2008104875A1
(en)
*
|
2007-03-01 |
2008-09-04 |
Pfizer Products Inc. |
Oxazolidinones as cholesterol absorption inhibitors
|
CA2675312A1
(en)
|
2007-03-06 |
2008-09-12 |
Teijin Pharma Limited |
1-biarylazetidinone derivative
|
TW200901959A
(en)
|
2007-03-09 |
2009-01-16 |
Indigene Pharmaceuticals Inc |
Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
|
WO2008123953A1
(en)
*
|
2007-04-02 |
2008-10-16 |
Merck & Co., Inc. |
Anti-hypercholesterolemic compound
|
WO2008130616A2
(en)
*
|
2007-04-19 |
2008-10-30 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
US8048880B2
(en)
*
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
US20090047716A1
(en)
*
|
2007-06-07 |
2009-02-19 |
Nurit Perlman |
Reduction processes for the preparation of ezetimibe
|
US20080318920A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Protia, Llc |
Deuterium-enriched ezetimibe
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
NZ582249A
(en)
*
|
2007-06-28 |
2012-06-29 |
Intervet Int Bv |
Substituted piperazines as cb1 antagonists
|
JP2010531874A
(ja)
*
|
2007-06-28 |
2010-09-30 |
インターベット インターナショナル ベー. フェー. |
Cb1アンタゴニストとしての置換ピペラジン
|
WO2009016358A2
(en)
*
|
2007-07-27 |
2009-02-05 |
Cipla Limited |
Pharmaceutical compositions and process for making them
|
WO2009024889A2
(en)
|
2007-08-21 |
2009-02-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
|
WO2009032264A1
(en)
*
|
2007-08-30 |
2009-03-12 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing intermediates of ezetimibe by microbial reduction
|
WO2009027785A2
(en)
*
|
2007-08-30 |
2009-03-05 |
Pfizer Products Inc. |
1, 3-oxazole derivatives as cetp inhibitors
|
DE102007063671A1
(de)
*
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
EP2965752A1
(de)
|
2007-12-10 |
2016-01-13 |
ratiopharm GmbH |
Pharmazeutische formulierung enthaltend ezetimib
|
CZ305066B6
(cs)
*
|
2008-02-25 |
2015-04-22 |
Zentiva, K.S. |
Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
|
EP2128133A1
(de)
|
2008-05-26 |
2009-12-02 |
Lek Pharmaceuticals D.D. |
Ezetiminverfahren und -zusammensetzung
|
WO2009147009A2
(en)
*
|
2008-06-06 |
2009-12-10 |
Nicox S.A. |
Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
|
US20090312302A1
(en)
*
|
2008-06-17 |
2009-12-17 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
|
WO2010025085A2
(en)
|
2008-08-29 |
2010-03-04 |
Codexis, Inc. |
Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
|
AU2009315314B2
(en)
|
2008-11-14 |
2013-04-18 |
Bomi P. Framroze |
A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis
|
EP2204170A1
(de)
|
2008-12-01 |
2010-07-07 |
LEK Pharmaceuticals D.D. |
Pharmazeutische Zusammensetzung mit Ezetimibe und Simvastatin
|
WO2010075069A1
(en)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Bicyclic pyranone derivatives as nicotinic acid receptor agonists
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
EP2216016A1
(de)
|
2009-02-06 |
2010-08-11 |
LEK Pharmaceuticals d.d. |
Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die Ezetimib umfasst
|
US9212175B2
(en)
|
2009-03-06 |
2015-12-15 |
Lipideon Biotechnology Ag |
Pharmaceutical hypocholesterolemic compositions
|
EP2229938B9
(de)
|
2009-03-13 |
2012-04-25 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Ezetimibzusammensetzungen
|
EP2414326B1
(de)
|
2009-03-31 |
2017-12-20 |
Lupin Limited |
Zwischenprodukte für die herstellung von 1,4-diphenylazetidinon
|
US9388440B2
(en)
|
2009-04-01 |
2016-07-12 |
Mylan Laboratories Limited |
Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
|
WO2011002424A2
(en)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Solubility and stability enchancing pharmaceutical formulation
|
WO2011002422A2
(en)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Solubility enhancing pharmaceutical formulation
|
WO2011019326A2
(en)
|
2009-07-02 |
2011-02-17 |
Mahmut Bilgic |
Solubility and stability enchancing pharmaceutical formulation
|
CN101993403B
(zh)
*
|
2009-08-11 |
2012-07-11 |
浙江海正药业股份有限公司 |
氮杂环丁酮类化合物及医药应用
|
WO2011022548A2
(en)
|
2009-08-19 |
2011-02-24 |
Codexis, Inc. |
Ketoreductase polypeptides for the preparation of phenylephrine
|
AU2011220745B2
(en)
|
2010-02-24 |
2016-12-01 |
Relypsa, Inc. |
Polyimidazoles for use as bile acid sequestrants
|
CA2790901C
(en)
|
2010-02-24 |
2018-05-01 |
Relypsa, Inc. |
Amine polymers for use as bile acid sequestrants
|
EP2539380B1
(de)
|
2010-02-24 |
2015-08-19 |
Relypsa, Inc. |
Vernetztes polyvinylamin, polyallalamin und polyethyleneimin zur verwendung als gallensäurekomplexbildner
|
EP2368543A1
(de)
|
2010-03-25 |
2011-09-28 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Verfahren zur Herstellung einer granulierten pharmazeutischen Zusammensetzung mit Simvastatin und/oder Ezetimibe
|
EP4241854A3
(de)
|
2010-04-23 |
2023-11-08 |
Alexion Pharmaceuticals, Inc. |
Enzym für die lysosomale speicherkrankheit
|
WO2011140219A1
(en)
|
2010-05-04 |
2011-11-10 |
Codexis, Inc. |
Biocatalysts for ezetimibe synthesis
|
ES2372460B1
(es)
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
Nuevo método para la preparación de ezetimiba.
|
SG188456A1
(en)
|
2010-09-09 |
2013-04-30 |
Synageva Biopharma Corp |
Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
|
DK3400944T3
(da)
|
2010-11-08 |
2020-10-12 |
Albireo Ab |
Ibat-inhibitorer til behandling af leversygdomme
|
CN103228270B
(zh)
|
2010-11-08 |
2016-02-10 |
阿尔比里奥公司 |
含ibat抑制剂和胆汁酸结合剂的药物组合
|
WO2012076030A1
(en)
|
2010-12-10 |
2012-06-14 |
Pharmathen S.A. |
Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
|
EP2675472A4
(de)
|
2011-02-15 |
2014-09-17 |
Synageva Biopharma Corp |
Verfahren zur behandlung von mangel an lysosomaler saurer lipase
|
US8455474B2
(en)
|
2011-03-04 |
2013-06-04 |
Mackay Memorial Hospital |
Method for treating tuberculosis
|
WO2012155932A1
(en)
|
2011-05-17 |
2012-11-22 |
Pharmathen S.A. |
Improved process for the preparation of ezetimibe
|
PL231215B1
(pl)
|
2011-06-15 |
2019-02-28 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
|
CN102675177A
(zh)
*
|
2011-06-28 |
2012-09-19 |
常州制药厂有限公司 |
一种降血脂药物及其关键中间体的制备方法
|
CN102952055A
(zh)
*
|
2011-08-16 |
2013-03-06 |
凯瑞斯德生化(苏州)有限公司 |
一种依泽替米贝和其中间体的制备方法
|
CN103204795B
(zh)
*
|
2012-01-11 |
2016-12-14 |
重庆华邦胜凯制药有限公司 |
一种手性氮杂环丁酮类化合物的制备方法
|
HUE052300T2
(hu)
|
2012-05-01 |
2021-04-28 |
Althera Life Sciences Llc |
Orális tablettakészítmény, amely a rozuvastatin és az ezetimib rögzített kombinációjából áll, hiperlipidémia és kardiovaszkuláris betegségek kezelésére
|
CN103570574B
(zh)
|
2012-07-20 |
2016-04-13 |
中国科学院上海有机化学研究所 |
一种依泽替米贝的合成方法及该方法中所用的中间体
|
CN103102297A
(zh)
*
|
2012-09-28 |
2013-05-15 |
北京赛林泰医药技术有限公司 |
一种新的依折麦布的合成方法
|
TW201427658A
(zh)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
|
CN103864708A
(zh)
*
|
2012-12-12 |
2014-06-18 |
天津市医药集团技术发展有限公司 |
一种依折麦布中间体的制备方法
|
WO2015039675A1
(en)
|
2013-09-23 |
2015-03-26 |
Pharmathen S.A. |
Novel process for the preparation of ezetimibe intermediates
|
EP3065736B1
(de)
|
2013-11-04 |
2018-11-14 |
Merck Sharp & Dohme Corp. |
Glucagon-rezeptor-antagonist-verbindungen, zusammensetzungen daraus und verfahren zur verwendung
|
WO2015092448A1
(en)
|
2013-12-18 |
2015-06-25 |
Rudjer Boskovic Institute |
Beta-lactam cholesterol absorption inhibitors
|
CN103739537B
(zh)
*
|
2013-12-24 |
2015-05-20 |
连云港恒运医药科技有限公司 |
依折麦布的新合成方法
|
KR20150079373A
(ko)
|
2013-12-30 |
2015-07-08 |
한미약품 주식회사 |
에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
|
CN103755616A
(zh)
*
|
2013-12-31 |
2014-04-30 |
北京万全德众医药生物技术有限公司 |
一种制备依泽替米贝异构体的方法
|
US10328082B2
(en)
|
2014-05-30 |
2019-06-25 |
Pfizer Inc. |
Methods of use and combinations
|
CN105294426B
(zh)
*
|
2014-06-09 |
2019-05-14 |
浙江海正药业股份有限公司 |
氮杂环丁酮化合物制备方法及其中间体
|
CN104447474A
(zh)
*
|
2014-11-11 |
2015-03-25 |
武汉武药科技有限公司 |
一种依折麦布异构体的合成方法
|
CN104387308A
(zh)
*
|
2014-11-18 |
2015-03-04 |
武汉福星生物药业有限公司 |
一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
|
CN104513187B
(zh)
*
|
2015-01-09 |
2017-05-31 |
安润医药科技(苏州)有限公司 |
依折麦布及其中间体的合成方法
|
JP2016145173A
(ja)
*
|
2015-02-09 |
2016-08-12 |
株式会社トクヤマ |
(3r,4s)‐1‐(4‐フルオロフェニル)‐[3(s)‐ヒドロキシ‐3‐(4‐フルオロフェニル)プロピル]‐(4‐ヒドロキシフェニル)‐2‐アゼチジノンの製造方法
|
SG11201707497UA
(en)
|
2015-03-13 |
2017-10-30 |
Esperion Therapeutics Inc |
Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
CN105287513A
(zh)
*
|
2015-10-23 |
2016-02-03 |
浙江永宁药业股份有限公司 |
一种依折麦布药物组合物及其制备方法
|
CN107098841A
(zh)
*
|
2016-02-19 |
2017-08-29 |
常州方楠医药技术有限公司 |
一种依折麦布的制备方法及该方法中所用的中间体
|
CN109791797B
(zh)
|
2016-12-05 |
2023-05-02 |
智慧芽信息科技(苏州)有限公司 |
在大数据库中根据化学结构相似性搜索和显示可用信息的系统、装置和方法
|
US20180338922A1
(en)
|
2017-05-26 |
2018-11-29 |
Esperion Therapeutics, Inc. |
Fixed dose formulations
|
EP3437636A1
(de)
|
2017-08-02 |
2019-02-06 |
Adamed sp. z o.o. |
Pharmazeutische zusammensetzung mit ezetimibe
|
US11408274B2
(en)
|
2018-01-16 |
2022-08-09 |
Q.E.D. Environmental Systems, Inc. |
Fluid level monitoring system and method incorporating pressure sensor system having inflatable/collapsible bag
|
CN113825839A
(zh)
|
2019-03-20 |
2021-12-21 |
雷杰纳荣制药公司 |
用固醇调节元件结合蛋白切割激活蛋白(scap)抑制剂治疗脂质水平升高
|
CN116889627A
(zh)
|
2019-03-20 |
2023-10-17 |
雷杰纳荣制药公司 |
用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
|
BR112022001783A2
(pt)
|
2019-07-31 |
2022-03-22 |
Tecnimede Soc Tecnico Medicinal Sa |
Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos.
|
EP4188338A1
(de)
|
2020-07-27 |
2023-06-07 |
KRKA, d.d., Novo mesto |
Zweischichtige tablette mit ezetimib und atorvastatin
|
AU2022291920A1
(en)
*
|
2021-06-17 |
2023-12-21 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Hybutimibe intermediate and preparation method therefor
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|